Multimodal therapy of idiopathic pyoderma gangrenosum

Dermatology Online Journal

Volumn 20, Issue 6, 2014, Pages

  Sharon, Victoria ^a   Burrall, Barbara ^a   Patel, Forum ^a   He, Yong ^a   Konia, Thomas ^a   Villalobos, Itzel Bustos ^a   Maverakis, Emanual ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Veteran Affairs Northern California Health Care System ^*  (United States)

Author keywords

Adalimumab; Neutrophilic dermatosis; Pyoderma gangrenosum; Treatment

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PREDNISONE;

ADOLESCENT; ANALOGS AND DERIVATIVES; BIOPSY; CASE REPORT; DEBRIDEMENT; FEMALE; HUMAN; LEG; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHYSICAL EXAMINATION; PYODERMA GANGRENOSUM;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY; COMBINED MODALITY THERAPY; CYCLOSPORINE; DEBRIDEMENT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEG; MYCOPHENOLIC ACID; PHYSICAL EXAMINATION; PREDNISONE; PYODERMA GANGRENOSUM;

EID: 84903534617     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Maverakis, E., et al., The etiology of paraneoplastic autoimmunity. Clin Rev Allergy Immunol, 2012. 42(2): p. 135-44.
2. Palombella, V., et al., The ubiquitin-proteasome pathway is required for processing the NF-kappa-B1 precursor protein and the activation of NF-kappa-B. Cell, 1994. 78: p. 773-785.
3. Siebenlist, U., G. Franzoso, and K. Brown, Structure, regulation, and function of NF-kB. Annu. Rev. Cell Biol, 1995. 10: p. 405-455.
4. Brooklyn, T., et al., Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006. 55(505-509).
5. Craig, F.F., et al., UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial. Trials, 2012. 13: p. 51.
6. Sivamani, R.K., et al., Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clin Rev Allergy Immunol, 2013. 44(2): p. 121-40.
7. Medeiros, C.C., et al., [Pyoderma gangrenosum in an infant: Case report]. Dermatol Online J, 2012. 18(7): p. 6.
8. Baumgart, D.C., B. Wiedenmann, and A.U. Dignass, Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis. Inflamm Bowel Dis, 2004. 10(4): p. 421-4.
9. Gilmour, E. and D. Stewart, Severe recalcitrant pyoderma gangrenosum responding to a combination of mycophenolate mofetil with cyclosporin and complicated by a mononeuritis. Br J Dermatol, 2001. 144: p. 397-400.
10. Nousari, H.C., et al., The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol, 1998. 134(12): p. 1509-11.
11. Teitel, A.D., Treatment of pyoderma gangrenosum with methotrexate. Cutis, 1996. 57(5): p. 326-8.
12. Venencie, P.Y. and J.H. Saurat, [Pyoderma gangrenosum in a child. Treatment with thalidomide (author's transl)]. Ann Pediatr (Paris), 1982. 29(1): p. 67-9.
13. Rozin, A., et al., Combined therapy for pyoderma gangrenosum. Ann Rheum Dis, 2004. 63: p. 888-889.
14. Fonder, M.A., et al., Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds, 2006. 5: p. e8.
15. Goodarzi, H., et al., Effective Strategies for the Management of Pyoderma Gangrenosum. Adv Wound Care (New Rochelle), 2012. 1(5): p. 194-199.